Belimumab: A Review in Systemic Lupus Erythematosus

Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting. Results of a large, multicentric, nationwide study

(2018) Luca Iaccarino et al.   JOURNAL OF AUTOIMMUNITY

Comparative efficacy and safety of intravenous or subcutaneous belimumab in combination with standard therapy in patients with active systemic lupus erythematosus: a Bayesian network meta-analysis of randomized controlled trials

(2017) Y H Lee et al.   LUPUS

A randomized, open-label study to investigate the effect of belimumab on pneumococcal vaccination in patients with active, autoantibody-positive systemic lupus erythematosus

(2017) W Chatham et al.   LUPUS

Belimumab use, clinical outcomes and glucocorticoid reduction in patients with systemic lupus erythematosus receiving belimumab in clinical practice settings: results from the OBSErve Canada Study

(2017) Zahi Touma et al.   RHEUMATOLOGY INTERNATIONAL

Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study

(2017) William Stohl et al.   Arthritis & Rheumatology

OP0039 Impact of Belimumab Use on Flares among Patients Diagnosed with Systemic Lupus Erythematosus (SLE) in A Us Commercially Insured Database: 2010-2014

(2016) M. Stott-Miller et al.   ANNALS OF THE RHEUMATIC DISEASES

Belimumab for the treatment of corticosteroid-dependent systemic lupus erythematosus: from clinical trials to real-life experience after 1 year of use in 48 Brazilian patients

(2016) Morton Scheinberg et al.   CLINICAL RHEUMATOLOGY

A Review of Clinical Trials of Belimumab in the Management of Systemic Lupus Erythematosus

(2016) Alexis Garcia et al.   CURRENT PHARMACEUTICAL DESIGN

Comparison of intravenous and subcutaneous exposure supporting dose selection of subcutaneous belimumab systemic lupus erythematosus Phase 3 program

(2016) S Wickramaratne Senarath Yapa et al.   LUPUS

Long-term organ damage accrual and safety in patients with SLE treated with belimumab plus standard of care

(2016) I N Bruce et al.   LUPUS

The global burden of SLE: prevalence, health disparities and socioeconomic impact

(2016) Erin E. Carter et al.   Nature Reviews Rheumatology

Effects of Belimumab on Flare Rate and Expected Damage Progression in Patients With Active Systemic Lupus Erythematosus

(2016) Luca Iaccarino et al.   ARTHRITIS CARE & RESEARCH

Cumulative Corticosteroid Dose Over Fifty-Two Weeks in Patients With Systemic Lupus Erythematosus: Pooled Analyses From the Phase III Belimumab Trials

(2016) Ronald F. van Vollenhoven et al.   Arthritis & Rheumatology

Immunogenicity to Biotherapeutics – The Role of Anti-drug Immune Complexes

(2016) Murli Krishna et al.   Frontiers in Immunology

Safety and Efficacy of Belimumab to Treat Systemic Lupus Erythematosus in Academic Clinical Practices

(2015) J. S. Hui-Yuen et al.   JOURNAL OF RHEUMATOLOGY

Assessment of the Economic Impact of Belimumab for the Treatment of Systemic Lupus Erythematosus in the Italian Setting: A Cost-Effectiveness Analysis

(2015) Francesca Pierotti et al.   PLoS One

Belimumab in systemic lupus erythematosus: a perspective review

(2015) Joyce S. Hui-Yuen et al.   Therapeutic Advances in Musculoskeletal Disease

Belimumab for the treatment of systemic lupus erythematosus

(2014) Natasha Jordan et al.   Expert Review of Clinical Immunology

Evaluation of Use of Belimumab In Clinical Practice Settings (Observe Study) In Spain: Health Resource Utilization and Labour Absenteeism

(2014) J. Cortés et al.   VALUE IN HEALTH

Cost-Effectiveness Analysis of Belimumab In the Treatment of Adult Systemic Lupus Erythematosus (Sle) Patients With Positive Biomarkers In Spain

(2014) L.A. Vallejo-Aparicio et al.   VALUE IN HEALTH

Belimumab for the Treatment of Systemic Lupus Erythematosus (Sle) In Greece: A Cost-Effectiveness and Cost-Utility Analysis

(2014) K. Athanasakis et al.   VALUE IN HEALTH

Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials

(2013) Vibeke Strand et al.   ANNALS OF THE RHEUMATIC DISEASES

Population Pharmacokinetics of Belimumab Following Intravenous Administration in Patients With Systemic Lupus Erythematosus

(2013) Herbert Struemper et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response

(2012) Ronald F van Vollenhoven et al.   ANNALS OF THE RHEUMATIC DISEASES

Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials

(2012) Susan Manzi et al.   ANNALS OF THE RHEUMATIC DISEASES

Effect of Belimumab on Vaccine Antigen Antibodies to Influenza, Pneumococcal, and Tetanus Vaccines in Patients with Systemic Lupus Erythematosus in the BLISS-76 Trial

(2012) W. WINN CHATHAM et al.   JOURNAL OF RHEUMATOLOGY

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

(2011) Richard Furie et al.   ARTHRITIS AND RHEUMATISM

Belimumab

(2011) Celeste B. Burness et al.   DRUGS

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

(2011) Sandra V Navarra et al.   LANCET

A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus

(2009) Daniel J. Wallace et al.   ARTHRITIS AND RHEUMATISM

Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus

(2008) Richard Furie et al.   ARTHRITIS RESEARCH & THERAPY